


Intracoronary Doppler Flow Velocity Profiles




Adenosine 18 μg
ic bolus

CVT-3146 30 μg
iv bolus

Figure 1

Dose-Dependent Increase in Peak Flow Velocity Caused by CVT-3146



CVT-3146 and Coronary Flow Velocity

Duration of Effect:

| Duration ≥2.5 Baseline | |
|------------------------|-------------------|
| Dose (n) | Mean ± SEM |
| 10 µg (4) | 0 |
| 30 µg (4) | 0 |
| 100 µg (3) | 0.2 ± 0.2 minutes |
| 300 µg (4) | 2.2 ± 1.3 minutes |
| 400 µg (8) | 2.8 ± 0.8 minutes |
| 500 µg (4) | 2.9 ± 1.3 minutes |

Figure 3

Time Course of APV Ratio (CVT-3146 400 μ g)





Figure 4

Time Course of Heart Rate (CVT-3146 400 µg)



Time Course of Blood Pressure (CVT-3146 400 μ g)




Figure 6

All Drug-Related Adverse Events Were Mild and Transient

| Adverse Event | All Doses | |
|--------------------------------------|-----------|-------------------|
| | (n = 36) | 400 µg (n = 9) |
| chest discomfort | 3 | 3 |
| increased heart rate | 3 | 1 |
| hypotension | 2 | 2 |
| flushing | 2 | 1 |
| shortness of breath | 2 | 0 |
| funny taste in mouth | 1 | 0 |
| sensation in mouth, sinus, and chest | 1 | 0 |
| headache | 1 | 0 |
| tingling in hands | 1 | 1 |
| heart racing | 1 | 1 |
| bradycardia | 1 | 1 |
| lightheadedness | 1 | 1 |
| cough | 1 | 0 |
| nausea and vomiting | 1 | 0 |

Figure 7

Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14





Figure 15






Figure 16




Figure 17




Figure 18